Inpria v. Lam Research: EUV Photoresist Patent Dispute Dismissed Without Prejudice

Case Overview

The Parties

The Patents at Issue

This landmark case involved eight U.S. patents asserted, spanning a sophisticated organometallic chemistry portfolio:

• • US10732505B1 — Monoalkyl tin compounds with low polyalkyl contamination
• • US9823564B2 — Organometallic solution-based high-resolution patterning compositions
• • US9310684B2 — Organometallic solution-based high-resolution patterning compositions and methods
• • US11693312B2 — Organotin oxide hydroxide patterning compositions and precursors
• • US11673903B2 — Patterned inorganic layers and radiation-based patterning compositions
• • US11809081B2 — Radiation-based patterning methods
• • US10642153B2 — High-resolution patterning compositions
• • US11537048B2 — Organometallic patterning compositions

Legal Representation

Plaintiff Inpria retained Fish & Richardson PC alongside Young, Conaway, Stargatt & Taylor LLP, assembling a 24-attorney team including lead counsel Naveen Modi, Eric W. Dittmann, and Joseph E. Palys.

Defendant Lam Research was represented by Morgan Lewis & Bockius LLP, Morris, Nichols, Arsht & Tunnell LLP, and Cross & Simon, LLC, fielding a 22-attorney team that included Michael J. Lyons, Matthew J. Moore, and Charles H. Sanders.

The depth of legal firepower on both sides reflects the high commercial stakes involved.

Litigation Timeline & Procedural History

Inpria filed suit on October 14, 2022, in the District of Delaware — the preferred venue for patent infringement cases involving sophisticated technology companies, owing to its experienced judiciary and established patent case management procedures.

The case ran for 1,067 days before closing on September 15, 2025, a duration consistent with complex multi-patent district court litigation involving significant claim construction disputes and technically demanding subject matter. Patent cases of this complexity typically encounter extensive discovery, multiple Markman briefing cycles, and potential inter partes review (IPR) proceedings at the USPTO — all of which can extend litigation timelines substantially.

Chief Judge Christopher J. Burke, a well-regarded jurist in Delaware patent matters, presided over the case. The specific procedural milestones — including any Markman hearings, summary judgment motions, or parallel USPTO proceedings — were not disclosed in the available case record. However, the case’s nearly three-year duration suggests substantive litigation activity before the parties reached their stipulated resolution.

The Verdict & Legal Analysis

Outcome

The action was resolved by stipulated dismissal without prejudice, meaning both parties jointly agreed to terminate the litigation without a final judgment on the merits. Crucially, a dismissal without prejudice preserves Inpria’s right to refile the same claims — a strategically significant distinction from a dismissal with prejudice, which would be claim-preclusive.

No damages were awarded. No injunctive relief was granted or denied on the merits. The specific terms of any accompanying settlement agreement, licensing arrangement, or business resolution between the parties were not publicly disclosed.

Verdict Cause Analysis

The case was brought as an infringement action — Inpria alleged that Lam Research’s products or processes fell within the scope of its asserted patent claims covering organometallic photoresist compositions and EUV patterning methods. The underlying legal questions likely included:

• Claim construction: The scope of functional and compositional claims covering tin-based photoresist formulations
• Literal infringement vs. doctrine of equivalents: Whether Lam’s specific chemistries and processes mapped to Inpria’s claim language
• Validity challenges: Given the nascent nature of inorganic EUV photoresist technology, prior art and written description arguments would be expected defenses
• IPR exposure: With eight patents at issue, Lam Research would have had strong incentives to pursue inter partes review petitions at the USPTO, potentially creating parallel invalidity proceedings that could influence litigation strategy

Because the dismissal was without prejudice and by stipulation, the court issued no claim construction order, validity ruling, or infringement finding on the public record. This leaves the patents’ scope and validity legally intact.

Legal Significance

The absence of a merits ruling means no binding precedent was established for organometallic photoresist patent claim construction in the Delaware District Court. For practitioners, this represents a double-edged outcome: Inpria’s patents remain unadjudicated and potentially enforceable against other parties, while Lam Research avoids an adverse judgment that could have constrained its technology roadmap.

Strategic Takeaways

For Patent Holders: Inpria’s multi-patent assertion strategy — deploying eight related patents across the same technology family — is a textbook portfolio enforcement approach. Layering patents across compositions, precursors, methods, and patterning applications creates overlapping claim coverage that complicates design-around efforts and strengthens licensing leverage.

For Accused Infringers: Lam Research’s response — engaging three separate law firms with deep patent litigation and semiconductor industry expertise — illustrates the defensive investment required to contest a well-constructed patent portfolio. Early-stage IPR petitions remain a critical defensive tool in multi-patent infringement actions involving technically complex chemistry patents.

For R&D Teams: The stipulated dismissal without prejudice means Inpria’s patent portfolio remains active and assertable. Companies developing EUV photoresist alternatives, delivery systems, or application processes should conduct rigorous freedom-to-operate (FTO) analyses against Inpria’s granted patent family before commercializing competing products.

Industry & Competitive Implications

The Inpria v. Lam Research dispute sits at the intersection of two of the semiconductor industry’s most strategically vital developments: EUV lithography adoption at advanced nodes and the race to commercialize next-generation photoresist materials that enable angstrom-scale patterning.

Inpria’s inorganic metal oxide photoresist technology has attracted significant industry attention, including a strategic acquisition by JSR Corporation — one of the world’s leading photoresist manufacturers — signaling the commercial value embedded in Inpria’s patent portfolio. This acquisition context makes the litigation’s resolution particularly meaningful: the dismissed claims remain available for future enforcement by JSR/Inpria against competitors or potential licensees.

For Lam Research, which has been actively expanding its chemical delivery and photoresist-related process capabilities, the resolution without a merits ruling avoids IP-related constraints on its EUV business development. However, the threat of refiling means Lam and similarly situated equipment and materials companies cannot treat this dismissal as a clean bill of health.

The broader semiconductor materials IP landscape — encompassing ASML, applied materials, photoresist suppliers, and emerging inorganic resist startups — should note this case as a marker of increasing IP assertion activity in the EUV photoresist field.